Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Deutsche Bank analyst David Hoang initiated coverage on Kymera Therapeutics Inc (NASDAQ:KYMR) with a Hold rating and announced a price target of $120. Kymera Therapeutics shares closed at $105.25 on Wednesday. See how other analysts view this stock.
• UBS analyst Nicolas Gaudois initiated coverage on SK Hynix Inc – ADR (NASDAQ:SKHY) with a Buy rating and announced a price target of $204. SK Hynix closed at $126.79 on Wednesday. See how other analysts view this stock.
• Rodman & Renshaw analyst Michael G. King Jr. initiated coverage on Actuate Therapeutics Inc (NASDAQ:ACTU) with a Buy rating and announced a price target of $6. Actuate Therapeutics shares closed at $1.08 on Wednesday. See how other analysts view this stock.

Considering buying SKHY stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.